Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
You will need to log in to participate in the activity.
The Impact of PI3K Inhibitors for the Treatment of Patients with Breast Cancer
Release Date: January 09, 2020
Expiration Date: January 09, 2021
Media: Internet - based
This continuing medical education (CME) activity is designed to inform healthcare providers who care for patients with breast cancer of the opportunities and challenges in the management of patients with breast cancer using phosphoinositide 3-kinase (PI3K) inhibitors. The in-depth program will cover best practices for identification of patients with breast cancer who are most likely to benefit from these agents, the specific mechanistic characteristics of available agents, and techniques for managing adverse events appropriately. In addition, available clinical trial data will be examined and contextualized in patient cases, including trials of emerging strategies utilizing combination approaches incorporating PI3K inhibition.
Benefits of Participating
- Learn the best approaches for identification of trials of PI3K inhibitors that may be appropriate for selected patients with breast cancer
- Outline clinical trials in progress and the latest developments on PI3K inhibitors in breast cancer
- Recognize the toxicity profile of PI3K inhibitors and latest strategies to diagnose and mitigate adverse events
Instructions for This Activity and Receiving Credit
Upon successful completion of this educational activity, you should be better prepared to:
- Explain the rationale for the use of PI3K inhibitors to treat patients with breast cancer.
- Outline the most important results from clinical trials exploring the use of PI3K inhibitors alone or in combination with other therapies for the treatment of patients with breast cancer.
- Implement strategies to identify and monitor adverse events associated with PI3K inhibitors to improve the outcome of patients with breast cancer.
Faculty, Staff, and Planners’ Disclosures
Vice Chair, Oncology Care
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, NY
Disclosures: Grant/Research Support: Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genetech/ Roche, Daiichi Sankyo, Carrick Pharm; Consultant: Genetech/ Roche, Pfizer, AstraZeneca, Merck, Puma Biotechnology, Advvaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme, Daiichi Sankyo; Speaker’s Bureau: Roche/Genetech.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER®.
This activity is funded by PER®.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.